Stock Analysis on Net

Gilead Sciences Inc. (NASDAQ:GILD)

Analysis of Profitability Ratios
Quarterly Data

Microsoft Excel

Profitability Ratios (Summary)

Gilead Sciences Inc., profitability ratios (quarterly data)

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Return on Sales
Gross profit margin 75.87% 78.66% 79.27% 78.94% 79.03% 74.31% 75.30% 75.50% 75.56% 80.23% 79.90% 80.32% 81.23% 78.72% 78.25% 79.06% 78.86%
Operating profit margin 28.24% 30.37% 31.18% 33.03% 27.17% 22.39% 25.78% 26.56% 36.72% 42.79% 37.20% 18.07% 16.72% 11.01% -4.40% 19.89% 19.38%
Net profit margin 21.03% 21.60% 20.18% 20.87% 17.02% 12.44% 15.22% 16.60% 23.05% 27.21% 19.62% 1.19% 0.51% 5.56% -1.18% 22.17% 24.35%
Return on Investment
Return on equity (ROE) 24.81% 26.33% 25.92% 26.59% 21.62% 15.82% 20.44% 22.66% 29.55% 34.44% 26.20% 1.59% 0.68% 7.27% -1.43% 22.49% 23.91%
Return on assets (ROA) 9.12% 9.42% 8.80% 9.02% 7.27% 5.33% 6.58% 7.16% 9.16% 11.02% 7.59% 0.45% 0.18% 2.08% -0.46% 8.31% 8.74%

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Profitability ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. Gilead Sciences Inc. gross profit margin ratio deteriorated from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Gilead Sciences Inc. operating profit margin ratio deteriorated from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Gilead Sciences Inc. net profit margin ratio improved from Q2 2023 to Q3 2023 but then slightly deteriorated from Q3 2023 to Q4 2023.

Profitability ratio Description The company
ROE A profitability ratio calculated as net income divided by shareholders’ equity. Gilead Sciences Inc. ROE improved from Q2 2023 to Q3 2023 but then deteriorated significantly from Q3 2023 to Q4 2023.
ROA A profitability ratio calculated as net income divided by total assets. Gilead Sciences Inc. ROA improved from Q2 2023 to Q3 2023 but then slightly deteriorated from Q3 2023 to Q4 2023.

Gross Profit Margin

Gilead Sciences Inc., gross profit margin calculation (quarterly data)

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data (US$ in millions)
Gross profit on product sales 4,980 5,429 5,122 4,905 5,936 5,583 4,696 5,110 4,533 6,133 4,762 4,979 5,930 5,352 4,003 4,498 4,113 4,481 4,607 4,243
Product sales 7,070 6,994 6,564 6,306 7,332 6,978 6,138 6,534 7,160 7,356 6,152 6,340 7,328 6,493 5,067 5,467 5,796 5,516 5,607 5,200
Profitability Ratio
Gross profit margin1 75.87% 78.66% 79.27% 78.94% 79.03% 74.31% 75.30% 75.50% 75.56% 80.23% 79.90% 80.32% 81.23% 78.72% 78.25% 79.06% 78.86%
Benchmarks
Gross Profit Margin, Competitors2
AbbVie Inc. 62.42% 65.76% 68.91% 69.43% 70.00% 69.62% 70.48% 69.53% 68.96% 67.72% 65.62% 64.82% 66.41% 68.74% 73.56% 77.43% 77.64%
Amgen Inc. 68.60% 72.35% 72.87% 73.65% 74.17% 73.99% 74.00% 73.30% 73.44% 74.00% 73.97% 74.37% 74.59% 75.55% 77.15% 78.90% 80.38%
Bristol-Myers Squibb Co. 76.24% 76.54% 77.01% 77.68% 78.04% 78.82% 79.13% 79.62% 78.57% 76.92% 75.88% 74.42% 72.31% 71.18% 69.47% 68.02% 69.10%
Eli Lilly & Co. 79.25% 78.67% 77.77% 77.67% 76.77% 75.61% 75.98% 74.40% 74.18% 74.85% 74.27% 75.88% 77.66% 78.26% 78.67% 79.22% 78.85%
Johnson & Johnson 68.82% 67.51% 67.09% 66.88% 67.26% 67.43% 67.86% 67.97% 68.16% 67.51% 67.00% 66.24% 65.58% 65.68% 65.66% 66.15% 66.42%
Merck & Co. Inc. 73.17% 72.86% 72.96% 72.43% 70.63% 70.49% 70.41% 70.72% 72.02% 67.95% 67.48% 66.99% 67.74% 71.23% 70.06% 70.11% 69.87%
Pfizer Inc. 57.34% 60.55% 69.42% 68.54% 65.77% 65.53% 62.18% 60.35% 62.08% 65.28% 70.96% 76.46% 79.26% 80.47% 80.19% 80.03% 80.25%
Regeneron Pharmaceuticals Inc. 86.16% 85.96% 86.42% 86.96% 87.18% 85.39% 84.97% 84.65% 84.83% 86.65% 86.85% 86.84% 86.82% 87.98% 88.21% 89.72% 90.05%
Thermo Fisher Scientific Inc. 39.90% 39.87% 39.75% 40.28% 42.24% 44.42% 46.63% 48.37% 50.08% 51.05% 51.29% 51.47% 49.67% 47.31% 45.39% 44.30% 44.35%
Vertex Pharmaceuticals Inc. 87.21% 87.80% 87.92% 88.04% 87.90% 88.00% 88.13% 87.95% 88.06% 87.94% 87.89% 88.06% 88.14% 88.01% 87.71% 87.24% 86.84%

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q4 2023 Calculation
Gross profit margin = 100 × (Gross profit on product salesQ4 2023 + Gross profit on product salesQ3 2023 + Gross profit on product salesQ2 2023 + Gross profit on product salesQ1 2023) ÷ (Product salesQ4 2023 + Product salesQ3 2023 + Product salesQ2 2023 + Product salesQ1 2023)
= 100 × (4,980 + 5,429 + 5,122 + 4,905) ÷ (7,070 + 6,994 + 6,564 + 6,306) = 75.87%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. Gilead Sciences Inc. gross profit margin ratio deteriorated from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.

Operating Profit Margin

Gilead Sciences Inc., operating profit margin calculation (quarterly data)

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data (US$ in millions)
Operating income (loss) 1,612 2,623 1,665 1,705 2,267 2,837 2,029 197 940 3,842 2,246 2,890 2,651 2,001 (2,983) 2,402 1,093 (1,473) 2,430 2,237
Product sales 7,070 6,994 6,564 6,306 7,332 6,978 6,138 6,534 7,160 7,356 6,152 6,340 7,328 6,493 5,067 5,467 5,796 5,516 5,607 5,200
Profitability Ratio
Operating profit margin1 28.24% 30.37% 31.18% 33.03% 27.17% 22.39% 25.78% 26.56% 36.72% 42.79% 37.20% 18.07% 16.72% 11.01% -4.40% 19.89% 19.38%
Benchmarks
Operating Profit Margin, Competitors2
AbbVie Inc. 23.49% 27.32% 31.03% 28.49% 31.21% 30.59% 30.33% 32.68% 31.89% 30.09% 28.95% 23.63% 24.81% 28.45% 30.17% 39.86% 39.03%
Amgen Inc. 29.35% 34.55% 37.50% 36.07% 38.57% 39.31% 38.04% 32.78% 31.44% 30.14% 30.72% 37.23% 37.70% 38.59% 39.76% 41.89% 43.57%
Bristol-Myers Squibb Co. 16.18% 16.96% 17.29% 18.13% 17.96% 19.04% 18.19% 16.79% 15.91% -15.73% -17.02% -19.19% -21.60% 9.27% 11.67% 16.30% 22.62%
Eli Lilly & Co. 18.92% 18.42% 24.17% 22.45% 24.97% 24.65% 25.50% 25.94% 22.45% 23.17% 21.81% 22.06% 24.69% 23.55% 24.48% 25.64% 22.29%
Johnson & Johnson 24.90% 25.19% 25.26% 25.04% 24.63% 23.89% 23.47% 23.76% 24.95% 24.69% 25.23% 24.10% 23.60% 24.30% 24.64% 25.62% 24.15%
Merck & Co. Inc. 3.92% 13.08% 10.34% 27.85% 30.27% 30.66% 33.04% 28.85% 25.74% 14.07% 10.64% 14.02% 16.47% 26.87% 25.40% 25.49% 24.77%
Pfizer Inc. 0.38% 13.44% 27.69% 34.30% 34.83% 33.59% 30.37% 26.12% 23.91% 24.67% 24.12% 21.20% 19.47% 21.17% 21.17% 24.20% 25.46%
Regeneron Pharmaceuticals Inc. 30.85% 32.23% 34.20% 35.79% 38.93% 45.45% 48.19% 55.08% 55.67% 55.19% 53.94% 43.37% 42.09% 37.43% 34.64% 30.45% 28.10%
Thermo Fisher Scientific Inc. 16.00% 15.81% 15.42% 16.29% 18.69% 20.54% 22.51% 23.83% 25.57% 27.04% 28.00% 27.68% 24.19% 20.90% 17.05% 17.86% 17.99%
Vertex Pharmaceuticals Inc. 38.83% 40.16% 41.72% 43.93% 48.23% 47.72% 48.85% 36.93% 36.73% 37.17% 33.93% 47.14% 46.03% 44.43% 38.67% 34.05% 28.77%

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q4 2023 Calculation
Operating profit margin = 100 × (Operating income (loss)Q4 2023 + Operating income (loss)Q3 2023 + Operating income (loss)Q2 2023 + Operating income (loss)Q1 2023) ÷ (Product salesQ4 2023 + Product salesQ3 2023 + Product salesQ2 2023 + Product salesQ1 2023)
= 100 × (1,612 + 2,623 + 1,665 + 1,705) ÷ (7,070 + 6,994 + 6,564 + 6,306) = 28.24%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Gilead Sciences Inc. operating profit margin ratio deteriorated from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.

Net Profit Margin

Gilead Sciences Inc., net profit margin calculation (quarterly data)

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data (US$ in millions)
Net income (loss) attributable to Gilead 1,430 2,180 1,045 1,010 1,640 1,789 1,144 19 382 2,592 1,522 1,729 1,551 360 (3,339) 1,551 2,696 (1,165) 1,880 1,975
Product sales 7,070 6,994 6,564 6,306 7,332 6,978 6,138 6,534 7,160 7,356 6,152 6,340 7,328 6,493 5,067 5,467 5,796 5,516 5,607 5,200
Profitability Ratio
Net profit margin1 21.03% 21.60% 20.18% 20.87% 17.02% 12.44% 15.22% 16.60% 23.05% 27.21% 19.62% 1.19% 0.51% 5.56% -1.18% 22.17% 24.35%
Benchmarks
Net Profit Margin, Competitors2
AbbVie Inc. 8.95% 11.81% 15.50% 13.37% 20.39% 23.19% 22.04% 22.00% 20.54% 13.66% 12.40% 10.28% 10.08% 18.16% 19.20% 24.77% 23.69%
Amgen Inc. 24.96% 29.52% 31.52% 31.77% 26.42% 27.88% 26.73% 23.42% 24.25% 23.03% 23.80% 29.60% 29.97% 30.91% 31.53% 33.64% 35.32%
Bristol-Myers Squibb Co. 17.83% 18.44% 17.62% 15.95% 13.71% 14.29% 14.04% 13.31% 15.08% -11.89% -11.44% -14.53% -21.20% -0.11% -1.61% 3.08% 13.15%
Eli Lilly & Co. 15.36% 15.55% 22.01% 20.54% 21.88% 20.63% 19.58% 20.90% 19.71% 21.52% 22.71% 23.91% 25.24% 24.01% 24.48% 23.97% 37.27%
Johnson & Johnson 41.28% 36.32% 13.35% 13.22% 18.90% 19.95% 19.21% 20.90% 22.26% 19.55% 19.92% 17.95% 17.82% 21.01% 18.86% 20.75% 18.42%
Merck & Co. Inc. 0.61% 7.77% 5.34% 22.52% 24.49% 25.88% 29.00% 26.27% 26.79% 15.09% 11.83% 15.09% 14.72% 24.33% 22.20% 21.10% 21.01%
Pfizer Inc. 3.62% 15.29% 27.55% 31.25% 31.27% 29.81% 28.94% 27.01% 27.04% 28.77% 23.86% 24.03% 22.95% 18.59% 31.31% 32.32% 31.45%
Regeneron Pharmaceuticals Inc. 30.14% 30.47% 33.93% 33.81% 35.64% 39.17% 39.97% 48.06% 50.25% 51.65% 50.11% 43.53% 41.35% 38.28% 37.30% 28.56% 26.91%
Thermo Fisher Scientific Inc. 13.99% 13.68% 13.14% 13.75% 15.47% 15.92% 17.37% 18.49% 19.70% 21.93% 22.47% 22.08% 19.79% 17.12% 14.12% 14.31% 14.47%
Vertex Pharmaceuticals Inc. 36.68% 35.94% 35.40% 35.40% 37.20% 37.62% 38.26% 30.84% 30.92% 30.52% 29.80% 43.06% 43.70% 44.91% 38.51% 31.35% 28.27%

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q4 2023 Calculation
Net profit margin = 100 × (Net income (loss) attributable to GileadQ4 2023 + Net income (loss) attributable to GileadQ3 2023 + Net income (loss) attributable to GileadQ2 2023 + Net income (loss) attributable to GileadQ1 2023) ÷ (Product salesQ4 2023 + Product salesQ3 2023 + Product salesQ2 2023 + Product salesQ1 2023)
= 100 × (1,430 + 2,180 + 1,045 + 1,010) ÷ (7,070 + 6,994 + 6,564 + 6,306) = 21.03%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Gilead Sciences Inc. net profit margin ratio improved from Q2 2023 to Q3 2023 but then slightly deteriorated from Q3 2023 to Q4 2023.

Return on Equity (ROE)

Gilead Sciences Inc., ROE calculation (quarterly data)

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data (US$ in millions)
Net income (loss) attributable to Gilead 1,430 2,180 1,045 1,010 1,640 1,789 1,144 19 382 2,592 1,522 1,729 1,551 360 (3,339) 1,551 2,696 (1,165) 1,880 1,975
Total Gilead stockholders’ equity 22,833 22,314 21,158 20,997 21,240 21,081 20,236 19,927 21,069 21,470 19,703 18,952 18,202 17,445 18,027 22,067 22,525 20,604 22,616 21,951
Profitability Ratio
ROE1 24.81% 26.33% 25.92% 26.59% 21.62% 15.82% 20.44% 22.66% 29.55% 34.44% 26.20% 1.59% 0.68% 7.27% -1.43% 22.49% 23.91%
Benchmarks
ROE, Competitors2
AbbVie Inc. 46.94% 53.86% 67.50% 57.14% 68.60% 83.83% 86.24% 76.64% 74.91% 55.60% 53.01% 37.63% 35.30% 48.34% 47.30%
Amgen Inc. 107.78% 98.82% 117.67% 148.04% 178.97% 187.11% 271.85% 624.78% 87.96% 68.26% 69.67% 75.91% 77.20% 67.09% 68.48% 80.92% 81.07%
Bristol-Myers Squibb Co. 27.27% 28.57% 24.91% 22.97% 20.37% 20.44% 20.30% 19.79% 19.46% -14.52% -13.80% -16.54% -23.84% -0.09% -1.15% 1.91% 6.66%
Eli Lilly & Co. 48.65% 44.46% 58.73% 50.82% 58.64% 59.91% 66.61% 65.69% 62.16% 76.99% 94.20% 88.31% 109.79% 115.45% 137.26% 179.72% 319.09%
Johnson & Johnson 51.11% 48.61% 17.37% 17.95% 23.36% 25.68% 24.05% 26.54% 28.20% 25.44% 25.53% 22.96% 23.25% 26.35% 24.11% 28.01% 25.42%
Merck & Co. Inc. 0.97% 11.17% 8.04% 27.82% 31.57% 34.32% 38.34% 34.68% 34.17% 20.10% 16.73% 26.08% 27.91% 39.47% 37.91% 38.72% 37.99%
Pfizer Inc. 2.38% 10.81% 21.68% 28.77% 32.79% 32.14% 33.61% 30.29% 28.47% 26.28% 18.86% 16.23% 15.21% 12.22% 22.05% 24.21% 25.77%
Regeneron Pharmaceuticals Inc. 15.22% 16.03% 17.90% 17.80% 19.14% 25.05% 27.49% 39.84% 43.03% 40.53% 41.02% 33.43% 31.86% 31.17% 32.94% 18.79% 19.08%
Thermo Fisher Scientific Inc. 12.83% 13.11% 13.08% 14.26% 15.80% 16.15% 17.59% 18.56% 18.94% 22.13% 23.32% 22.60% 18.47% 15.33% 12.41% 12.85% 12.45%
Vertex Pharmaceuticals Inc. 20.59% 21.01% 21.75% 22.59% 23.88% 25.12% 26.77% 22.47% 23.19% 22.83% 21.66% 30.76% 31.22% 33.08% 27.67% 23.38% 19.34%

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q4 2023 Calculation
ROE = 100 × (Net income (loss) attributable to GileadQ4 2023 + Net income (loss) attributable to GileadQ3 2023 + Net income (loss) attributable to GileadQ2 2023 + Net income (loss) attributable to GileadQ1 2023) ÷ Total Gilead stockholders’ equity
= 100 × (1,430 + 2,180 + 1,045 + 1,010) ÷ 22,833 = 24.81%

2 Click competitor name to see calculations.

Profitability ratio Description The company
ROE A profitability ratio calculated as net income divided by shareholders’ equity. Gilead Sciences Inc. ROE improved from Q2 2023 to Q3 2023 but then deteriorated significantly from Q3 2023 to Q4 2023.

Return on Assets (ROA)

Gilead Sciences Inc., ROA calculation (quarterly data)

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data (US$ in millions)
Net income (loss) attributable to Gilead 1,430 2,180 1,045 1,010 1,640 1,789 1,144 19 382 2,592 1,522 1,729 1,551 360 (3,339) 1,551 2,696 (1,165) 1,880 1,975
Total assets 62,125 62,373 62,337 61,876 63,171 62,557 62,870 63,080 67,952 67,098 67,984 67,492 68,407 60,878 55,934 59,741 61,627 59,146 63,210 62,837
Profitability Ratio
ROA1 9.12% 9.42% 8.80% 9.02% 7.27% 5.33% 6.58% 7.16% 9.16% 11.02% 7.59% 0.45% 0.18% 2.08% -0.46% 8.31% 8.74%
Benchmarks
ROA, Competitors2
AbbVie Inc. 3.61% 4.78% 6.42% 5.64% 8.53% 9.49% 8.83% 8.71% 7.88% 5.06% 4.50% 3.43% 3.07% 4.93% 4.65% 9.25% 8.84%
Amgen Inc. 6.91% 8.36% 8.84% 8.92% 10.06% 10.73% 11.09% 9.67% 9.63% 8.63% 9.61% 11.33% 11.54% 11.37% 11.23% 12.45% 13.13%
Bristol-Myers Squibb Co. 8.43% 9.08% 8.52% 7.75% 6.53% 6.80% 6.59% 6.07% 6.40% -4.87% -4.58% -5.53% -7.61% -0.04% -0.44% 0.74% 2.65%
Eli Lilly & Co. 8.19% 8.61% 11.85% 10.70% 12.62% 12.71% 12.09% 13.06% 11.44% 12.39% 12.70% 13.01% 13.28% 12.68% 13.39% 13.46% 21.17%
Johnson & Johnson 20.98% 20.85% 6.81% 6.49% 9.57% 10.94% 10.33% 11.12% 11.47% 9.98% 10.07% 8.76% 8.41% 9.95% 9.59% 11.07% 9.59%
Merck & Co. Inc. 0.34% 4.32% 2.98% 12.09% 13.30% 14.25% 15.48% 13.29% 12.35% 7.70% 6.14% 7.73% 7.72% 12.83% 11.56% 11.95% 11.66%
Pfizer Inc. 0.94% 4.87% 9.75% 14.85% 15.91% 15.32% 15.01% 13.58% 12.11% 11.10% 7.78% 7.01% 6.23% 4.46% 7.97% 9.47% 9.72%
Regeneron Pharmaceuticals Inc. 11.95% 12.41% 14.02% 13.91% 14.85% 19.40% 20.90% 30.11% 31.75% 29.55% 28.88% 22.53% 20.47% 19.62% 20.68% 14.46% 14.29%
Thermo Fisher Scientific Inc. 6.07% 6.12% 6.08% 6.36% 7.15% 7.77% 8.21% 8.20% 8.12% 11.64% 12.70% 12.02% 9.23% 7.62% 6.02% 6.25% 6.33%
Vertex Pharmaceuticals Inc. 15.92% 15.97% 16.54% 17.18% 18.30% 19.59% 20.50% 17.19% 17.44% 17.25% 16.30% 22.80% 23.07% 23.81% 20.37% 16.99% 14.15%

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q4 2023 Calculation
ROA = 100 × (Net income (loss) attributable to GileadQ4 2023 + Net income (loss) attributable to GileadQ3 2023 + Net income (loss) attributable to GileadQ2 2023 + Net income (loss) attributable to GileadQ1 2023) ÷ Total assets
= 100 × (1,430 + 2,180 + 1,045 + 1,010) ÷ 62,125 = 9.12%

2 Click competitor name to see calculations.

Profitability ratio Description The company
ROA A profitability ratio calculated as net income divided by total assets. Gilead Sciences Inc. ROA improved from Q2 2023 to Q3 2023 but then slightly deteriorated from Q3 2023 to Q4 2023.